Biogen Inc. on Monday cut the price of its Alzheimer’s drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits. The U.S. Food and Drug Administration (FDA) approved the drug, Aduhelm, in June to treat the brain-wasting disease despite the view of its outside advisory panel that Biogen had not proven the treatment’s clinical benefit. The U.S. Medicare program, which pays for health services for people over 65 years, has scheduled a January meeting for a national policy for the drug, making reimbursement more difficult in the interim. Biogen’s $56,000 per year treatment price for an average weight person was seen as a significant cost burden on Medicare, which covers more than 60 million people. The company said it hoped the new annual price of $28,200 will expand access to the …